[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605778":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":50,"collaborators":12,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":12,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":34,"whyStopped":12,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual care","NO_INTERVENTION","usual care",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention","ACTIVE_COMPARATOR","Airsupra PRN",[18],"Drug: Airsupra",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Airsupra","1 dose (2 inhalations) PRN, with maximum of 6 doses (12 inhalations) in a 24-hour period",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Carlos A Camargo, MD, DrPH","CONTACT","617-726-5276","ccamargo@mgb.org",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"MetroHealth","RECRUITING","Cleveland","Ohio","44109","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-81.69541,41.4995,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":29,"phoneExt":12,"email":49},"Charles L Emerman, MD","cemerman@metrohealth.org",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Carlos A. Camargo, Jr.","Physician","100605778","phase-4-45th-multicenter-airway-research-collaboration-100605778",false,"NCT07166939","45th Multicenter Airway Research Collaboration","A Phase 4, Multicenter, Cluster Randomized, Open-label, Intervention Versus Usual Care, Controlled Study on the Effect of Emergency Department Initiation of Airsupra on Asthma Outcomes","MARC-45","INCLUSION CRITERIA:\n\n* acute asthma\n* age 18.0 to 54.9 years\n* English and\u002For Spanish speaking\n* decision by ED attending to discharge patient to home on short course of systemic corticosteroids\n* (intervention group only) Willingness to use Airsupra as their rescue inhaler for next 3 months\n* demonstration of acceptable MDI administration technique\n* provision of informed consent prior to any study-specific procedures\n\nEXCLUSION CRITERIA:\n\n* involvement in the planning and\u002For conduct of the study\n* previous enrolment in the present study\n* prior diagnosis of COPD, chronic bronchitis, or emphysema\n* use of systemic corticosteroids in the past 2 weeks\n* participation in another clinical study with an investigational product during the past 4 weeks or the 3 months after enrollment in the current study\n* concurrent pneumonia\n* clinically significant cardiovascular disease or clinically significant cancer\n* patients with known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any of the excipients of the product\n* (for women only, by self-report):\n* currently pregnant\n* currently breastfeeding,\n* (among sexually active women of child-bearing age only) not using adequate contraception over the last 3 months, or no plan to use adequate contraception over the next 3 months\n* lack of a working cell phone and working email address\n* expected lack of availability for text and\u002For telephone follow-up at approximately 3, 6, and 12 weeks after the ED visit\n* inability to provide an alternate contact with a working cell phone and working email address.","ALL","18 Years","54 Years",{"count":66,"type":67},1860,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma \"recurrence\" at 3 months and other related outcomes (acute asthma relapse, asthma control).",[73,74,75,76],"Asthma Acute","Asthma Exacerbation","Asthma","Asthma Control Level",[78,79,80,81,82,83,84,85,86],"asthma","emergency department","airsupra","randomized trial","acute asthma recurrence","acute asthma relapse","asthma control","acute asthma","asthma exacerbation","2026-04-14",{"date":89,"type":90},"2026-04-17","ACTUAL",{"date":92,"type":90},"2025-11-07",{"date":94,"type":67},"2027-06",{"name":5,"class":6},1]